Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

An AE was any untoward medical occurrence attributed to a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug to the end of study (Day 126), that were absent before treatment or that worsened relative to pre-treatment state. AEs include both SAEs and all non-SAEs.

Clinically significant ECG findings included: heart rate (HR): less than or equal to (<=) 45 beats per minute (bpm) or greater than or equal to (>=)120 bpm or decrease/increase of >=15 bpm from baseline value, PR interval: >=220 millisecond (msec) and change of >=20 msec from baseline value and; QRS interval >=120 msec; corrected QT (QTc) interval for men greater than (>) 450 msec, QTc interval for women >470 msec.

Criteria for identifying vital sign values of PCI: heart rate: increase of >15 bpm from baseline value and >=120 bpm and decrease of >15 bpm from baseline value and <=45 bpm; Sitting and Supine systolic blood pressure (SBP): increase of >=20 millimeters of mercury (mm Hg) from baseline value and >=160 mm Hg and decrease of >=20 mm Hg from baseline value and <=90 mm Hg; Sitting and Supine diastolic blood pressure (DBP): increase of >=15 mm Hg from baseline value and >=100 mm Hg and decrease of >=15 mm Hg from baseline value and <=50 mm Hg; Respiratory rate: <10 or >25 breaths/minute; Weight: >=7 percent increase or decrease from baseline value; Oral temperature: <35 degree Celsius (C) or >38.3 degree C.

Criteria:Hematocrit:5% decrease from baseline,Hemoglobin:decrease of >=20 gram per liter(g/L) from baseline,WBC: <3.0*10^9/L;neutrophils: <1.5*10^9/L,platelet count:<100*10^9/L,eosinophils: >0.5*10^9/L;prothrombin time,partial thromboplastin time: >1.5*Upper limit of normal(ULN);sodium,potassium: >5millimoles per liter(mmol/L)aboveULN/below lower limit of normal(LLN),creatinine: >1.36*ULN,urea: >1.5*ULN,glucose(fasting): >0.83mmol/L above ULN/below ULN,glucose (non-fasting): >5.0 mmol/L above ULN/>0.56 mmol/L below LLN,calcium:change of >=0.25 mmol/L from baseline,magnesium:change at >=0.21mmol/L from baseline value,phosphorus:>0.162 mmol/L above ULN/below LLN,total protein:change of >=20 g/L from baseline,albumin:change of >=10 g/L from baseline,uric acid:change of >0.119mmol/L from baseline,creatine kinase: >3*ULN,cholesterol: >7.77mmol/L,triglycerides:>3.39mmol/L;ALT,AST,total bilirubin: >2*ULN,alkaline phosphatase: >1.5*ULN,Gamma-glutamyl transferase,lactate dehydrogenase: >3*ULN.

The terminal-phase disposition rate constant measured by a log-linear regression of the terminal mono exponential portion of the observed plasma concentrations, expressed in 1/day.

The terminal-phase disposition rate constant measured by a log-linear regression of the terminal mono exponential portion of the observed plasma concentrations, expressed in 1/day.

Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half.

Plasma terminal half-life is the time measured for the plasma concentration to decrease by one half.

AUClast is defined as area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration.

AUC (0-312) = Area under the plasma concentration time-curve from time zero (pre-dose) to 312 hours (0-312) postdose of ILV-094.

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after IV dose (apparent clearance) was influenced by the fraction of the dose absorbed.

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Cavg was the average plasma concentration of drug during the dosing interval.

Rac was estimated as: X*AUClast of Day 1 divided by AUC312 of Day 42, where X is the ratio of the maintenance dose to the loading dose of ILV-094, AUClast is defined as area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration and AUC-312 is the AUC from time 0 to 312 hours on Day 42.

CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation.

PASI score is the combined assessment of lesion severity and area affected into single score range on a scale of 0 (no disease) to 72 (maximal disease), with higher scores indicating greater severity of psoriasis. Body divided into 4 sections (head and neck [h], arms [u], trunk [t], legs [l]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

TLS was based on the severity of 3 components: erythema, induration, and scaling. Severity of each component was evaluated on a 5-point scale as: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked, with higher scores reflected increased lesion severity. Scores of 3 components were summed to derive the total target lesion score, ranging from 0=none to 12=very marked, with higher scores reflected increased lesion severity.

Physician global assessment of disease activity was measured on an 11-point scale, ranging from 0 = no disease activity to 10 = extreme disease activity, where higher scores indicating greater disease activity.

Participants with their ADA titer levels >=6.23 were considered to be ADA positive. Participants with at least 1 positive ADA titer are reported.